WallStreetZen

NYSE: NVO
Novo Nordisk A S Stock Forecast, Predictions & Price Target

Analyst price target for NVO

Based on 0 analysts offering 12 month price targets for Novo Nordisk A S.
Insufficient data to display

Should I buy or sell NVO stock?

Based on 1 analysts offering ratings for Novo Nordisk A S.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

NVO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Deutsche Bank
Top 46%
55
Strong BuyInitiates Coverage OnN/AN/A2021-01-15

1 of 1

Forecast return on equity

Is NVO forecast to generate an efficient return?
Company
112.84%
Industry
17.39%
Market
17.31%
NVO's Return on Equity is forecast to be high in 3 years (112.84%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is NVO forecast to generate an efficient return on assets?
Company
46.79%
Industry
6.38%
NVO is forecast to generate higher Return on Assets (46.79%) than the US Biotechnology industry average (6.38%)
Forecast

NVO earnings per share forecast

What is NVO's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$3.22+4.99%
Avg 2 year Forecast
$3.59+17.05%
Avg 3 year Forecast
$4.23+37.92%
NVO's earnings are forecast to grow at a rate of 10.8% per year, which is not exceptional
Forecast

NVO revenue forecast

What is NVO's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$22.1B+6.36%
Avg 2 year Forecast
$24.6B+18.53%
Avg 3 year Forecast
$27.1B+30.48%
NVO's revenue is forecast to grow at a rate of 9.45% per year, which is not exceptional
Forecast

NVO earnings growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
10.8%
Industry
34.39%
Market
18.33%
NVO's earnings are forecast to grow slower (10.8% per year) than the US Biotechnology industry average (34.39%)
Forecast
NVO's earnings are forecast to grow slower (10.8% per year) than the US market average (18.33%)
Forecast
NVO's earnings are forecast to grow faster (10.8% per year) than the risk-free savings rate (1.7%)
Forecast

NVO revenue growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
9.45%
Industry
45.94%
Market
11.75%
NVO's revenues are forecast to grow slower (9.45% per year) than the US Biotechnology industry average (45.94%)
Forecast
NVO's revenues are forecast to grow slower (9.45% per year) than the US market average (11.75%)
Forecast

Novo Nordisk A S Stock Forecast FAQ

Is Novo Nordisk A S Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 1 Wall Street analysts covering (NYSE: NVO) stock is to Strong Buy NVO stock.

Out of 1 analysts, 1 (100%) are recommending NVO as a Strong Buy, 0 (0%) are recommending NVO as a Buy, 0 (0%) are recommending NVO as a Hold, 0 (0%) are recommending NVO as a Sell, and 0 (0%) are recommending NVO as a Strong Sell.

What is NVO's earnings growth forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's forecast annual earnings growth rate of 10.8% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 34.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.33%.

Novo Nordisk A S's earnings in 2021 is $7,064,012,738.On average, 4 Wall Street analysts forecast NVO's earnings for 2021 to be $7,408,576,000, with the lowest NVO earnings forecast at $7,063,456,000, and the highest NVO earnings forecast at $7,592,640,000. On average, 4 Wall Street analysts forecast NVO's earnings for 2022 to be $8,259,872,000, with the lowest NVO earnings forecast at $7,661,664,000, and the highest NVO earnings forecast at $8,973,120,000.

In 2023, NVO is forecast to generate $9,732,384,000 in earnings, with the lowest earnings forecast at $8,927,104,000 and the highest earnings forecast at $10,537,664,000.

What is NVO's revenue growth forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of 9.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.75%.

Novo Nordisk A S's revenue in 2021 is $20,686,305,732.On average, 2 Wall Street analysts forecast NVO's revenue for 2021 to be $50,866,512,048,000, with the lowest NVO revenue forecast at $50,351,190,368,000, and the highest NVO revenue forecast at $51,381,833,728,000. On average, 2 Wall Street analysts forecast NVO's revenue for 2022 to be $56,684,625,536,000, with the lowest NVO revenue forecast at $55,139,868,416,000, and the highest NVO revenue forecast at $58,229,382,656,000.

In 2023, NVO is forecast to generate $62,398,351,728,000 in revenue, with the lowest revenue forecast at $59,960,895,712,000 and the highest revenue forecast at $64,835,807,744,000.

What is NVO's forecast return on assets (ROA) for 2021-2024?

(NYSE: NVO) forecast ROA is 46.79%, which is higher than the forecast US Biotechnology industry average of 6.38%.

What is NVO's Price Target?

According to 0 Wall Street analysts that have issued a 1 year NVO price target, the average NVO price target is N/A, with the highest NVO stock price forecast at N/A and the lowest NVO stock price forecast at N/A.

On average, Wall Street analysts predict that Novo Nordisk A S's share price could stay at N/A by Jan 15, 2022. The average Novo Nordisk A S stock price prediction forecasts a potential downside of N/A from the current NVO share price of $106.01.

What is NVO's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's current Earnings Per Share (EPS) is $3.05. On average, analysts forecast that NVO's EPS will be $3.22 for 2021, with the lowest EPS forecast at $3.07, and the highest EPS forecast at $3.30. On average, analysts forecast that NVO's EPS will be $3.59 for 2022, with the lowest EPS forecast at $3.33, and the highest EPS forecast at $3.90. In 2023, NVO's EPS is forecast to hit $4.23 (min: $3.88, max: $4.58).

What is NVO's forecast return on equity (ROE) for 2021-2024?

(NYSE: NVO) forecast ROE is 112.84%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.